Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04295148

SEQUAR SEmitendinosus vs QUadriceps in Anterior Cruciate Ligament Reconstruction

Randomized control trial comparing two different Anterior Cruciate Ligament (ACL) grafts in Anterior Cruciate Ligament Reconstruction: the semitendinosus hamstrings graft and the quadriceps graft. Capio Artro Clinic (Stockholm) has vast experience in ACL surgery using both semitendinosus and quadriceps grafts.

Recruiting

Interested in participating?

Request Info

Key information

Age range

16 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Capio Artro Clinic AB

Stockholm, Stockholm County, 11428, Sweden

Location status: Recruiting

Location contact

Anders Stålman, MD, PhD

CONTACT

Anders Stålman, MD,PhD

PRINCIPAL_INVESTIGATOR

Daniel Castellanos, MD

PRINCIPAL_INVESTIGATOR

Joanna Kvist, PhD

PRINCIPAL_INVESTIGATOR

Mikael Östlin, MD

PRINCIPAL_INVESTIGATOR

Vasileios Sarakatsianos, MD

PRINCIPAL_INVESTIGATOR

About this study

The purpose of the study is to evaluate the quadriceps graft with bone-plug in Anterior Cruciate Ligament Reconstruction (ACL-R) and compare it with the most common choice of graft, semitendinosus hamstrings graft in ACL-R in athletes with Tegner Activity Scale 7 or higher. Both methods are well-known and continually registered in the Swedish ACL Registry.

Both grafts will be compared post operatively as to knee laxity (primary outcome), PROMs, as well as measure graft site morbidity, Return to Sports rate, and the post-operative rehab. At 9 months we will also preform a MRI scan to determine graft maturity. 5-year and 10-year data will also be acquired through the Swedish ACL-registry and Lysholm score and Tegner Activity Level score. At 10-year a plain weight baring X-ray will be preformed to evaluate development of osteoarthritis.

The study design is a prospective randomized study with equal groups:

Semitendinosus graft (=100) and Quadriceps tendon graft (n=100). According to historical material from Capio Artro Clinic (Stockholm) the following power calculation has been made: Significance lever 5 percent (p=0.05) and power is 80%. The difference between the groups is 1 mm knee laxity with KT-1000 which would give an effect size of 0,44 or less compared to an average effect size (0,50). 85 individuals will be needed in each group in the statistical analysis. Although no stratification for sex will be performed, our aim is to have a balanced representation of sex that reflects the typical patient population for this condition at the clinic, with a distribution of 40% females and 60% males across both groups. Inclusion will continue until we have at least 100 individuals in each group. This means that each group can have more than 100 individuals. Randomization process and study design will be done according to the CONSORT guidelines.

Initially, the study was designed to have two primary outcome measures: KT-1000 knee laxity at 6 months and KOOS at 24 months. However, the study is only powered for the first outcome (Knee Laxity measured with KT-1000), therefore KOOS will be followed as a secondary outcome measure.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pre-injury Tegner Activity Scale≥7
  • Intended return to sports to prior sport and Tegner Activity Scale Level
  • Time between injury and inclusion not more than 6 months
  • MR verified ACL rupture

Exclusion criteria

  • Previous knee injury with symptoms before ACL injury
  • Neurological disease, inflammatory disease, connective tissue disease or balance disorder
  • Previous lower limb fracture or surgery
  • Laxity in the medial collateral ligament (MCL) and lateral collateral ligament (LCL) > grade 1
  • PCL rupture or Multiligament knee injury (MLKI)
  • Radiographic sign of osteoarthritis (OA)
  • Previous knee surgery or ligament injury in contralateral knee
  • Beighton score ≥ 5

Treatment and study plan

ACL Reconstruction with Semitendinosus graft

Procedure

Participants will undergo Anterior Cruciate Ligament Reconstruction with Semitendinosus graft

Other names: ACL-R with Semitendinosus graft, Semitendinosus ACL-R

ACL Reconstruction with Quadriceps tendon-bone graft

Procedure

Participants will undergo Anterior Cruciate Ligament Reconstruction with Quadriceps tendon-bone graft

Other names: ACL-R with Quadriceps tendon-bone graft, Quad tendon-bone ACL-R

Primary outcomes

  1. KT-1000 Knee Laxity at 6 months

    Time frame: Pre-operative appointment and 6 months post-operative appointments

    The KT-1000 measures laxity objective- and parametrically and is a validated tool for establishing joint laxity post operatively in mm.

Secondary outcomes

  1. KOOS

    Time frame: Pre-operative appointment, 12 months, 24 months, 5 years and 10 years post-operative appointments

    Patients will complete the KOOS at specific time points to evaluate subjective knee function throughout treatment

  2. IKDC

    Time frame: Pre-operative appointment, 12 months, 24 months, 5 years and 10 years post-operative appointments

    Patients will complete the IKDC at specific time points to evaluate subjective knee function throughout treatment.

  3. PAS

    Time frame: Pre-operative appointment, 12 months, 24 months, 5 years and 10 years post-operative appointments

    Patients will complete the PAS at specific time points to evaluate subjective knee function throughout treatment

  4. EQ5D

    Time frame: Pre-operative appointment, 12 months, 24 months, 5 years and 10 years post-operative appointments

    Patients will complete the EQ5D at specific time points to evaluate subjective knee function throughout treatment

  5. Tegner Activity Score

    Time frame: Pre-operative appointment, 6 months, 9 months, 12 months, 18 months, 24 months, 5 years and 10 years post-operative appointments

    Patients will complete the Tegner Activity score at specific time points to evaluate level of sports activity postoperatively.

  6. ACL-RSI

    Time frame: 6 months and 12 months, post-operative appointments

    Patients will complete the ACL-RSI surveys at specific time points to evaluate self efficacy and readiness to return to sports throughout treatment

  7. Return to Sports Questionnaire

    Time frame: 6 months, 9 months and 12 months, 18 months, and 24 months post-operative appointments

    Patients will complete the a Return to Sports Questionnaire at specific time points to evaluate return to sports after 6 and 12 months throughout treatment

  8. Werner anterior knee pain score

    Time frame: 6 weeks, 6 months, 9 months, and 12 months

    Patients will complete Werner anterior knee pain scores at specific time points to evaluate graft site pain/morbidity throughout treatment

  9. Kartus anterior knee pain score

    Time frame: 6 weeks, 6 months, 9 months, and 12 months

    Patients will complete Kartus anterior knee pain score at specific time points to evaluate graft site pain/morbidity throughout treatment

  10. Graft site morbidity questionnaire

    Time frame: 6 weeks, 6 months, 12 months, 24 months

    Patients will complete additional survey questions at specific time points to evaluate graft site pain/morbidity throughout treatment

  11. Goniometric measurement: Knee extension and flexion

    Time frame: 2 weeks, 6 weeks, 6 months, 9 months and 12 months

    Patients will undergo goniometric measurement at specific time points to evaluate knee moment throughout treatment.

  12. Measurement of circumference of the knee

    Time frame: 2 weeks, 6 weeks, 6 months, 9 months and 12 months

    Circumference of the knee will be measured at mid-patella and 15 cm above superior border of the patella. They will be compared with the contralateral knee to compare knee swelling.

  13. Biodex Isokinetic Measurement

    Time frame: 6 months, 9 months and 12 months

    Patients will undergo Biodex Isokinetic measurement at specific time points to muscle strength throughout treatment.

  14. Functional knee tests

    Time frame: 6 months, 9 months and 12 months

    Patients will undergo functional knee test (ie one legged jump and crossover jump) at specific time points to evaluate functional knee movement throughout treatment.

  15. Lachmans test

    Time frame: Pre-operative appointment , 6 months, 9 months and 12 months

    Patients will undergo passive accessory stability tests Lachmans test (graded 0,1,2 and 3) at specific time points to evaluate passive knee laxity throughout treatment.

  16. Pivot shift test

    Time frame: Pre-operative appointment , 6 months, 9 months and 12 months

    Patients will undergo passive accessory stability tests pivot shift test (graded 0,1,2 and 3) at specific time points to evaluate passive knee laxity throughout treatment.

  17. Time to Return to Sports Rates

    Time frame: 6 months, 9 months, 12 months, 18 months, 24 months

    Time to return to sports will be evaluated through Return to Sport surveys at specific time points throughout treatment

  18. Graft failure rate or ACL re-rupture

    Time frame: 10 years

    ACL reconstruction will be evaluated by graft failure rate or ACL re-rupture during a 10 year period

  19. ACL re-operation

    Time frame: 10 years

    ACL reconstruction will be evaluated by re-operation rate during a 10 year period

  20. Graft maturity

    Time frame: 9 months

    Graft maturity after ACL reconstruction will be evaluated by MRI at 9 months postoperatively.

  21. 10 year X-Ray

    Time frame: 10 years

    Development of osteoarthritis after ACL reconstruction will be evaluated by plain weight baring X-rays at 10 years.

Study contacts

Contact information is provided by the study sponsor or research team.

Anders Stålman, MD,Phd

CONTACT

[email protected]

0046736665957

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Registry information

Official study title

SEQUAR - SEmitendinosus vs QUadriceps in Anterior Cruciate Ligament Reconstruction - a Prospective Randomized Study

Acronym: SEQUAR

Important dates

Study start
2020
Primary completion
2027
Study completion
2035
First posted
Mar 4, 2020
Registry last updated
Sep 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.